S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Authors: Tsao, Anne S., Hsieh, Ming-Hui, Koczywas, Marianna, Tu, Janet, Riess, Jonathan, Tanvetyanon, Tawee, Ma, Barbara T., Zhao, Ying-Qi, Redman, Mary W., Edelman, Martin J., Gandara, David R., Gray, Jhanelle E., Kelly, Karen L.

Source: In JTO Clinical and Research Reports December 2024 5(12)

Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Authors: Kozono, David, Hua, Xing, Wu, Michael C., Tolba, Khaled A., Waqar, Saiama N., Dragnev, Konstantin H., Cheng, Haiying, Hirsch, Fred R., Mack, Philip C., Gray, Jhanelle E., Kelly, Karen, Borghaei, Hossein, Herbst, Roy S., Gandara, David R., Redman, Mary W.

Source: In Journal of Thoracic Oncology December 2024 19(12):1618-1629

Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors

Authors: Reduzzi, Carolina, Nicolo’, Eleonora, Singhal, Surbhi, Venetis, Konstantinos, Ortega-Franco, Ana, de Miguel-Perez, Diego, Dipasquale, Angelo, Gouda, Mohamed A., Saldanha, Erick F., Kasi, Pashtoon M., Jantus-Lewintre, Eloisa, Fusco, Nicola, Malapelle, Umberto, Gandara, David R., Rolfo, Christian, Serrano, Maria Jose, Cristofanilli, Massimo

Source: In Critical Reviews in Oncology / Hematology November 2024 203

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study

Authors: Riess, Jonathan W., Lara, Matthew S., Lopez de Rodas, Miguel, Luxardi, Guillaume, Herbert, Samantha, Shimoda, Michiko, Kelly, Karen, Meerlev, Alexander, Moore, Elizabeth, Beckett, Laurel, Monjazeb, Arta, Schalper, Kurt, Maverakis, Emanual, Gandara, David R.

Source: In JTO Clinical and Research Reports October 2024 5(10)

27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study

Authors: Saltman, David L., Varga, Matthew G., Nielsen, Tyler J., Croteau, Nicole S., Lockyer, Heather M., Jain, Amit L., Vidal, Gregory A., Hout, David R., Schweitzer, Brock L., Seitz, Robert S., Ross, Douglas T., Gandara, David R.

Source: Clinical lung cancer. 24(2):137-144

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183343343.0x000001&indx=1&recIds=ETOCvdc_100183343343.0x000001

Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer

Authors: Al-Obeidi, Ebaa, Riess, Jonathan W., Malapelle, Umberto, Rolfo, Christian, Gandara, David R.

Source: In Hematology/Oncology Clinics of North America June 2023 37(3):475-487

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

Authors: Reckamp, Karen L., Redman, Mary W., Dragnev, Konstantin H., Minichiello, Katherine, Villaruz, Liza C., Faller, Bryan, Al Baghdadi, Tareq, Hines, Susan, Everhart, Leah, Highleyman, Louise, Papadimitrakopoulou, Vassiliki, Gandara, David R., Kelly, Karen, Herbst, Roy S.

Source: Journal of clinical oncology. 40(21):2295-2306

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100167477114.0x000001&indx=1&recIds=ETOCvdc_100167477114.0x000001

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial

Authors: Gadgeel, Shirish, Hirsch, Fred R., Kerr, Keith, Barlesi, Fabrice, Park, Keunchil, Rittmeyer, Achim, Zou, Wei, Bhatia, Namrata, Koeppen, Hartmut, Paul, Sarah M., Shames, David, Yi, Jing, Matheny, Christina, Ballinger, Marcus, McCleland, Mark, Gandara, David R.

Source: Clinical lung cancer. 23(1):21-33

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100153309237.0x000001&indx=1&recIds=ETOCvdc_100153309237.0x000001

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Authors: Hirsch, Fred R., Redman, Mary W., Moon, James, Agustoni, Francesco, Herbst, Roy S., Semrad, Thomas J., Varella-Garcia, Marileila, Rivard, Chris J., Kelly, Karen, Gandara, David R., Mack, Philip C.

Source: Clinical lung cancer. 23(1):60-71

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100153309102.0x000001&indx=1&recIds=ETOCvdc_100153309102.0x000001

Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer

Authors: Gandara, David R., Subramanian, Janakiraman, Santos, Edgardo S., Brody, Yehuda, Sela, Itamar, Elon, Yehonatan, Harel, Michal, Reiner-Benaim, Anat, Lahav, Coren, McGregor, Kimberly

Source: In Clinical Lung Cancer September 2024 25(6):e252-e261

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

Authors: Riess, Jonathan W, Reckamp, Karen L, Frankel, Paul, Longmate, Jeffrey, Kelly, Karen A, Gandara, David R, Weipert, Caroline M, Raymond, Victoria M, Keer, Harold N, Mack, Philip C, Newman, Edward M, Lara, Primo N, Jr.

Source: In Clinical Lung Cancer November 2021 22(6):541-548

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Authors: Argiris, Athanassios, Miao, Jieling, Cristea, Mihaela C., Chen, Allen M., Sands, Jacob M., Decker, Roy H., Gettinger, Scott N., Daly, Megan E., Faller, Bryan A., Albain, Kathy S., Yanagihara, Ronald H., Garland, Linda L., Byers, Lauren A., Wang, Ding, Koczywas, Marianna, Redman, Mary W., Kelly, Karen, Gandara, David R.

Source: In Clinical Lung Cancer July 2021 22(4):313-323

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

Authors: Steuer, Conor E., Jegede, Opeyemi A., Dahlberg, Suzanne E., Wakelee, Heather A., Keller, Steven M., Tester, William J., Gandara, David R., Graziano, Stephen L., Adjei, Alex A., Butts, Charles A., Ramalingam, Suresh S., Schiller, Joan H.

Source: In Journal of Thoracic Oncology June 2021 16(6):960-967

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Authors: Owonikoko, Taofeek K., Redman, Mary W., Byers, Lauren A., Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Al Baghdadi, Tareq, Lara, Primo, Jr., Miao, Jieling, Kelly, Karen, Ramalingam, Suresh S., Herbst, Roy S., Papadimitrakopoulou, Vassiliki, Gandara, David R.

Source: In Clinical Lung Cancer May 2021 22(3):187-194

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Authors: Borghaei, Hossein, Redman, Mary W., Kelly, Karen, Waqar, Saima N., Robert, Francisco, Kiefer, Gauri J., Stella, Philip J., Minichiello, Katherine, Gandara, David R., Herbst, Roy S., Papadimitrakopoulou, Vassiliki A.

Source: In Clinical Lung Cancer May 2021 22(3):178-186

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Authors: Waqar, Saiama N., Redman, Mary W., Arnold, Susanne M., Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Gandara, David R., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tanna, Saloni H., Raddin, Ryan S., Minichiello, Katherine, Bradley, Jeffrey D., Kelly, Karen, Herbst, Roy S., Papadimitrakopoulou, Vassiliki A.

Source: In Clinical Lung Cancer May 2021 22(3):170-177

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

Authors: Mazieres, Julien, Rittmeyer, Achim, Gadgeel, Shirish, Hida, Toyoaki, Gandara, David R., Cortinovis, Diego L., Barlesi, Fabrice, Yu, Wei, Matheny, Christina, Ballinger, Marcus, Park, Keunchil

Source: In Journal of Thoracic Oncology January 2021 16(1):140-150

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design

Authors: Riess, Jonathan W., Frankel, Paul, Shackelford, David, Dunphy, Mark, Badawi, Ramsey D., Nardo, Lorenzo, Cherry, Simon R., Lanza, Ian, Reid, Joel, Gonsalves, Wilson I., Kunos, Charles, Gandara, David R., Lara, Primo N., Newman, Edward, Paik, Paul K.

Source: Clinical lung cancer. 22(1):67-70

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134862199.0x000001&indx=1&recIds=ETOCvdc_100134862199.0x000001

Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer

Authors: Malapelle, Umberto, Pisapia, Pasquale, Addeo, Alfredo, Arrieta, Oscar, Bellosillo, Beatriz, Cardona, Andres F., Cristofanilli, Massimo, De Miguel-Perez, Diego, Denninghoff, Valeria, Durán, Ignacio, Jantus-Lewintre, Eloísa, Nuzzo, Pier Vitale, O'Byrne, Ken, Pauwels, Patrick, Pickering, Edward M., Raez, Luis E., Russo, Alessandro, Serrano, Maria José, Gandara, David R., Troncone, Giancarlo, Rolfo, Christian

Source: Expert review of molecular diagnostics. 21(11):1165-1178

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100134791762.0x000001&indx=1&recIds=ETOCvdc_100134791762.0x000001

CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.

Authors: Al-Obeidi, Ebaa, Kelly, Karen, Gandara, David R., Riess, Jonathan W.

Source: JCO Precision Oncology; 12/1/2024, Vol. 8, p1-6, 6p

Subject Terms: EPIDERMAL growth factor, OSIMERTINIB, ANTINEOPLASTIC agents, LUNG cancer, NON-small-cell lung carcinoma